• Understand the risk factors that contribute to the elevated risk for thrombotic cardiovascular events pre- and post-myocardial infarction in patients across the coronary artery disease spectrum.
  • Differentiate oral P2Y12 inhibitors with respect to their clinical pharmacology and examine the select differences between oral antiplatelet therapies.
  • Describe the role of BRILINTA in reducing the risk of cardiovascular events in patients with acute coronary syndrome, history of myocardial infarction, and high-risk coronary artery disease without prior myocardial infarction.

This content is developed exclusively by or on behalf of the industry sponsor through a third party and is not reviewed by Pri-Med. The content and opinions expressed are those of the sponsor or presenters and may not reflect the views of Pri-Med.



Ted Okerson, MD, FACP, FACE

Dr. Okerson currently serves as a Sr. Field Physician within the Biopharmaceuticals US Medical Team for AstraZeneca’s Division of Cardiovascular and Metabolic Diseases. Dr. Okerson has a diverse medical and scientific background, with over 15 years of full-time clinical practice and leadership experience. For the past twenty years, he has exemplified a successful transition to industry, working as a Medical Director in various aspects of the pharmaceutical industry from clinical trial design to late phase clinical development and medical affairs for various well-known companies. In his current role, Dr. Okerson educates HCPs, works across specialties for internal collaborations, and strives to improve patient care.

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.